跳转至内容

尊敬的客户:

目前国际形势复杂多变,关税政策尚不明朗,这可能对我们的产品价格产生一定影响。在此情况下,我们希望就订单事宜与您进行友好沟通。

基于当前的不确定性,如果您选择在此期间下单,我们将保留根据实际情况调整价格的权利。同时,我们也理解市场变化可能给您带来的困扰,因此如果在订单实际发货前因关税政策变动导致价格出现较大波动,默克将与您进行协商讨论并视情况对订单进行调整或取消。

关于应对近期政策变化的重要更新,请点击此处查看详情。

Merck
CN
  • Discriminating promiscuous from target-specific autoantibodies in COVID-19.

Discriminating promiscuous from target-specific autoantibodies in COVID-19.

European journal of immunology (2023-03-02)
Mikhail Lebedin, Clara Vázquez García, Lisa Spatt, Christoph Ratswohl, Charlotte Thibeault, Lennard Ostendorf, Tobias Alexander, Friedemann Paul, Leif Erik Sander, Florian Kurth, Kathrin de la Rosa
摘要

Diverse autoantibodies were suggested to contribute to severe outcomes of COVID-19, but their functional implications are largely unclear. ACE2, the SARS-CoV-2 receptor and a key regulator of blood pressure, was described to be one of many targets of autoantibodies in COVID-19. ACE2 in its soluble form (sACE2) is highly elevated in the blood of critically ill patients, raising the question of whether sACE2:spike complexes induce ACE2 reactivity. Screening 247 COVID-19 patients, we observed elevated sACE2 and anti-ACE2 IgG that were poorly correlated. Interestingly, levels of IgGs recognizing ACE2, IFNα2, and CD26 strongly correlated in severe COVID-19, with 15% of sera showing polyreactivity versus 4.1% exhibiting target-directed autoimmunity. Promiscuous autoantibodies failed to impair the activity of ACE2 and IFNα2, while only specific anti-IFNα2 IgG compromised cytokine function. Our study suggests that the detection of autoantibodies in COVID-19 is often attributed to a promiscuous reactivity, potentially misinterpreted as target-specific autoimmunity with functional impact.

材料
货号
品牌
产品描述

Sigma-Aldrich
Z-脯氨酸, ≥98% (HPLC)
登录查看公司和协议定价
货号包装规格是否有货价格数量
5 mL
国内现货,预计发货时间 2025年4月21日
详情...
¥1,689.45